蘇州高新(600736.SH):認購杭州銀行可轉債298.449萬張
格隆匯 3 月 30日丨蘇州高新(600736.SH)公佈,2021年3月25日,杭州銀行披露了《杭州銀行公開發行可轉換公司債券發行公吿》,公司作為其A股股東,享有可轉債優先配售權。截至目前,公司持有杭州銀行A股股票118,010,988股,根據上述《發行公吿》,公司可優先配售的杭州銀行可轉債金額為29844.9萬元。
2021年3月29日,公司通過交易系統認購杭州銀行可轉債298.449萬張,單價為100元/張,共計投資資金29844.9萬元。2021年3月30日,杭州銀行披露了《杭州銀行公開發行可轉換公司債券網上中籤率及網下配售結果公吿》確定最終發行結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.